The Venture Codex Logo

The Venture Codex

Regeneron Pharmaceuticals

777 Old Saw Mill River Road, Tarrytown, NY, 10591, United States

Overview

Biopharmaceutical company developing treatments for serious medical conditi

Founded

1988

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series B
Series C

Geographic focus

The Netherlands
United States

Sector focus

Biopharma
Biotechnology
Pharmaceutical

Investment portfolio

7rounds
NAMEDATESIZE
Truveta
Jan 2025Participated
$320 MSeries C
Sonoma BioTherapeutics
Sep 2024Led
$45 MOther Equity
Vyriad
May 2022Participated
$30 MSeries B
ISA Pharmaceuticals
Jul 2021Participated
$31 MOther Equity
DNAnexus
Jun 2020Participated
$100 MSeries G
Adicet Bio
Oct 2019Participated
$80 MSeries B
Decibel Therapeutics
Jun 2018Participated
$55 MSeries C
Truveta
Jan 2025Participated
$320 MSeries C
Sonoma BioTherapeutics
Sep 2024Led
$45 MOther Equity
Vyriad
May 2022Participated
$30 MSeries B
ISA Pharmaceuticals
Jul 2021Participated
$31 MOther Equity
DNAnexus
Jun 2020Participated
$100 MSeries G
Adicet Bio
Oct 2019Participated
$80 MSeries B
Decibel Therapeutics
Jun 2018Participated
$55 MSeries C
7
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Regeneron Pharmaceuticals: 7 funding rounds are recorded in the selected participation categories.All available history.
Regeneron Pharmaceuticals: 7 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series B02
Series C+03
Other Equity11

Monthly Deal Activity

Regeneron Pharmaceuticals: 7 deals are recorded across 101 months.All available history.
Regeneron Pharmaceuticals: 7 deals are recorded across 101 months. All available history
MonthDeals
Jun '181
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '191
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '201
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '211
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '221
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '241
Oct '240
Nov '240
Dec '240
Jan '251
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Regeneron Pharmaceuticals: Health & Life Sciences is the largest displayed sector by deal count (7 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Regeneron Pharmaceuticals: Health & Life Sciences is the largest displayed sector by deal count (7 deals). All available history
SectorDeals
Health & Life Sciences7
Enterprise Software1
Data, Analytics & IT1
Space & Frontier Tech1

Deal Size Distribution

Regeneron Pharmaceuticals: 7 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Regeneron Pharmaceuticals: 7 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M3
$50M-$100M2
$100M-$250M1
$250M-$500M1
$500M-$1B0
$1B+0

Deals By Geography

Regeneron Pharmaceuticals: United States has the largest recorded deal count among the displayed regions (6 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Regeneron Pharmaceuticals: United States has the largest recorded deal count among the displayed regions (6 deals). All available history
RegionDeals
United States6
Europe1
Regeneron Pharmaceuticals: 20 co-investors are shown, with Foresite Capital sharing 2 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Regeneron Pharmaceuticals: 20 co-investors are shown, with Foresite Capital sharing 2 recorded deals. All available history
Co-investorShared deals
Foresite Capital2
Google Ventures2
aMoon1
Bessemer Trust1
Consensus Business Group1
DSC Investment1
First Round1
Handok1
Illumina1
Invest-NL1
Johnson & Johnson Innovation1
KB Investment1
Longevity Venture Partners1
Mayo Clinic1
Mirae Asset1
Northpond Ventures1
Novartis1
OCI Enterprises1
OrbiMed1
Perceptive Advisors1

Investment Strategy

Regeneron Pharmaceuticals: Led accounts for 14% and participating for 86% of round participation.All available history.
Regeneron Pharmaceuticals: Led accounts for 14% and participating for 86% of round participation. All available history
CategoryDeals (count)Share (%)
Led114%
Participating686%
Regeneron Pharmaceuticals: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
Regeneron Pharmaceuticals: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead1100%
Co-led00%

Team

Aris Baras

Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center

David Weinreich

Executive Vice President, Head, Global Clinical Development

George D. Yancopoulos

President, Chief Scientific Office & co-Founder

Gregory Geba

Senior Vice President, Global Development Scientific Council

Leonard S. Schleifer

Founder, President, and Chief Executive Officer

Michael Selzer

Manager, Combination Products Engineering

Nanita Cranford

Executive Director, Head of Global Regulatory Operations

Ned Braunstein

Senior Vice President, Regulatory Affairs

Neil Stahl

SVP Research and Development Sciences

Nouhad Husseini

Business Development